Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sIPV vaccine + hepatitis A inactivated vaccine + MMR vaccine
- Development stage
- Unknown
- Lead developer
- Institute of Medical Biology Chinese Academy of Medical Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This is a combination immunization regimen involving three separate vaccines administered concomitantly: the Sabin strain-based Inactivated Poliovirus Vaccine (sIPV), an inactivated Hepatitis A virus (HAV) vaccine, and the Measles-Mumps-Rubella (MMR) live attenuated viral vaccine. The sIPV induces immunity by presenting killed poliovirus antigens to elicit neutralizing antibodies against all three poliovirus serotypes. The hepatitis A inactivated vaccine contains purified, formalin-inactivated HAV to stimulate protective anti-HAV antibody production. The MMR is a trivalent live attenuated viral preparation that induces cellular and humoral immune responses against measles virus, mumps virus, and rubella virus. These vaccines are typically administered as part of routine childhood immunization schedules; co-administration has been shown not to interfere with individual immune responses or safety profiles[1][2]. Each component targets prevention of its respective disease.
- Brand names
- VAQTAProQuad
- Other names
- inactivated poliovirus vaccine (sIPV)hepatitis A vaccine, inactivatedmeasles, mumps, and rubella vaccine
02
Targets
Mumps virus antigenMV (Measles virus)Hepatitis A virus capsid protein
Beyond the preview
Go deeper on sIPV vaccine + hepatitis A inactivated vaccine + MMR vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sIPV vaccine + hepatitis A inactivated vaccine + MMR vaccine.